Skip to main content
Search
Main content
An alpha synuclein protein

Lewy body dementia

What is Lewy body dementia? 

Lewy body dementia is one of the more common types of dementia and is characterised by the build-up of abnormal clumps of protein (called Lewy bodies) gathering inside brain cells.

The disease particularly affects a person’s ability to think and move and can cause hallucinations, changes in alertness, and sleep disturbances. It tends to develop slowly and get gradually worse over several years. In the early stages, it is often mistaken for Alzheimer’s disease and can be diagnosed incorrectly.

Lewy body dementia has two subtypes: Dementia with Lewy bodies, and Parkinson’s disease dementia. These subtypes can affect people in very similar ways, and the diagnosis of one or the other depends only on the onset and timing of certain symptoms.

Woman holding up ribbon in activity class

Frequently asked questions

How common is Lewy body dementia?
What are the symptoms of Lewy body dementia?
How is Lewy body dementia diagnosed?
What treatments are available for Lewy body dementia?
How can I get involved in research and trials for Lewy body dementia?
Support for Lewy body dementia

What causes Lewy body dementia?

Lewy body dementia is caused by small, round clumps of protein building up inside nerve cells in the brain. One of these proteins is called alpha-synuclein, and the clumps it forms are called Lewy bodies.

These deposits are also found in most people with Parkinson's disease, and they build up in areas of the brain responsible for functions such as thinking, visual perception and muscle movement. The symptoms that people with Lewy body dementia will experience depend on where the Lewy bodies are found in the brain. 

Similar to other neurodegenerative conditions, it is not clear why the deposits develop and how exactly they damage the brain, although there is growing evidence that the proteins affect the brain’s normal functions by interfering with signals sent between brain cells. As with other dementias, it is likely that many factors contribute to disease initiation and progression including ageing, and dysfunction of the immune and vascular systems. 

Researchers such as Dr Tim Bartels and Prof David Klenerman have collaborated to help identify the exact toxic of alpha-synucein showing that it changes over the course of the condition. This finding could have significant implications for the timing of future treatments.

Additionally, as Lewy body dementia and Parkinson’s are both characterised by the same toxic protein build-up – alpha-synuclein – insights into the underlying biological mechanisms can be shared in many cases. Find out more on the Parkinson’s disease condition page.

Video showing lightsheet microscopy of a whole mouse brain cleared of lipids and fat, and stained for alpha-synuclein tagged with florescent marker. Credit: James Conway, Bartels Lab.